[go: up one dir, main page]

WO2011009039A3 - Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie - Google Patents

Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie Download PDF

Info

Publication number
WO2011009039A3
WO2011009039A3 PCT/US2010/042253 US2010042253W WO2011009039A3 WO 2011009039 A3 WO2011009039 A3 WO 2011009039A3 US 2010042253 W US2010042253 W US 2010042253W WO 2011009039 A3 WO2011009039 A3 WO 2011009039A3
Authority
WO
WIPO (PCT)
Prior art keywords
mgbg
pharmaceutical
methods
oral delivery
treating disease
Prior art date
Application number
PCT/US2010/042253
Other languages
English (en)
Other versions
WO2011009039A2 (fr
Inventor
John Mckearn
Jeremy Blitzer
Original Assignee
Pathologica Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112012000862A priority Critical patent/BR112012000862A8/pt
Priority to JP2012520810A priority patent/JP6112449B2/ja
Priority to AU2010273277A priority patent/AU2010273277B2/en
Priority to CA2768018A priority patent/CA2768018C/fr
Priority to HK13103363.8A priority patent/HK1176548B/xx
Priority to EP10800602.4A priority patent/EP2453886B1/fr
Priority to DK10800602.4T priority patent/DK2453886T3/en
Priority to ES10800602T priority patent/ES2715173T3/es
Application filed by Pathologica Llc filed Critical Pathologica Llc
Priority to CN201080041853.XA priority patent/CN102686222B/zh
Priority to EP18210165.9A priority patent/EP3473247A1/fr
Priority to NZ597488A priority patent/NZ597488A/en
Publication of WO2011009039A2 publication Critical patent/WO2011009039A2/fr
Publication of WO2011009039A3 publication Critical patent/WO2011009039A3/fr
Priority to AU2016266049A priority patent/AU2016266049B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)

Abstract

L'invention porte sur de nouvelles compositions pharmaceutiques orales de MGBG et d'analogues de polyamine associés, d'inhibiteurs de la biosynthèse de polyamine, d'inhibiteurs de polyamine de AMD-I et de régulateurs d'ostéopontine, et sur leur application pour le traitement d'une maladie.
PCT/US2010/042253 2009-07-16 2010-07-16 Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie WO2011009039A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DK10800602.4T DK2453886T3 (en) 2009-07-16 2010-07-16 ORGANIC ADMINISTRATION COMPREHENSIVE MGBG AND DISEASE METHODS
AU2010273277A AU2010273277B2 (en) 2009-07-16 2010-07-16 Pharmaceutical for oral delivery comprising MGBG and methods of treating disease
CA2768018A CA2768018C (fr) 2009-07-16 2010-07-16 Produit pharmaceutique pour administration par voie orale comprenant mgbg et procedes de traitement de maladie
HK13103363.8A HK1176548B (en) 2009-07-16 2010-07-16 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
EP10800602.4A EP2453886B1 (fr) 2009-07-16 2010-07-16 Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
BR112012000862A BR112012000862A8 (pt) 2009-07-16 2010-07-16 composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
EP18210165.9A EP3473247A1 (fr) 2009-07-16 2010-07-16 Composition pour administration par voie orale comprenant la mgbg pour utilisation dans le traitement de la sclérose en plaque
ES10800602T ES2715173T3 (es) 2009-07-16 2010-07-16 Producto farmacéutico para administración oral que comprende MGBG y métodos de tratamiento de enfermedades
CN201080041853.XA CN102686222B (zh) 2009-07-16 2010-07-16 包含mgbg的口服递送药物以及治疗疾病的方法
JP2012520810A JP6112449B2 (ja) 2009-07-16 2010-07-16 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
NZ597488A NZ597488A (en) 2009-07-16 2010-07-16 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
AU2016266049A AU2016266049B2 (en) 2009-07-16 2016-12-01 Pharmaceutical for oral delivery comprising MGBG and methods of treating disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22606009P 2009-07-16 2009-07-16
US61/226,060 2009-07-16
US29009509P 2009-12-24 2009-12-24
US61/290,095 2009-12-24

Publications (2)

Publication Number Publication Date
WO2011009039A2 WO2011009039A2 (fr) 2011-01-20
WO2011009039A3 true WO2011009039A3 (fr) 2011-06-16

Family

ID=43450234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042253 WO2011009039A2 (fr) 2009-07-16 2010-07-16 Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie

Country Status (11)

Country Link
US (4) US8258186B2 (fr)
EP (2) EP2453886B1 (fr)
JP (4) JP6112449B2 (fr)
CN (2) CN102686222B (fr)
AU (2) AU2010273277B2 (fr)
BR (1) BR112012000862A8 (fr)
CA (1) CA2768018C (fr)
DK (1) DK2453886T3 (fr)
ES (1) ES2715173T3 (fr)
NZ (3) NZ628513A (fr)
WO (1) WO2011009039A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627676T3 (es) 2007-03-09 2017-07-31 Pathologica Llc MGBG para la regulación de osteopontina y el tratamiento de la esclerosis múltiple
EP2453886B1 (fr) 2009-07-16 2018-12-12 Pathologica LLC Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
US9675566B2 (en) * 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
NO2665471T3 (fr) 2011-01-19 2018-05-26
WO2013083813A2 (fr) * 2011-12-07 2013-06-13 Universität Zürich Modulateurs de la spermine/spermidine n'-acétyltransférase (ssat) et protéines associées à la ssat pour une utilisation dans la prévention ou le traitement de la polyarthrite rhumatoïde
US20140107218A1 (en) * 2012-10-15 2014-04-17 Nestec Sa Methods for maintaining eye health and ameliorating opthalmic maladies in animals
CA2896977C (fr) 2013-01-08 2021-12-07 Pathologica Llc Methodes et compositions pour le traitement des troubles de demyelinisation
US10632145B2 (en) 2016-03-25 2020-04-28 Aminex Therapeutics, Inc. Bioavailable polyamines
WO2018027149A1 (fr) * 2016-08-04 2018-02-08 University Of Miami Procédés de traitement du syndrome d'alport
JP6840386B2 (ja) * 2017-04-26 2021-03-10 学校法人 関西大学 細胞足場材料製造用組成物ならびに細胞足場材料およびその製造方法
EP4126017A4 (fr) * 2020-04-03 2024-05-22 Baylor College of Medicine La signalisation tnf-alpha déclenche une inflammation activant une tumeur qui peut être ciblée pour une thérapie
WO2022072586A1 (fr) 2020-09-30 2022-04-07 Aminex Therapeutics, Inc. Combinaison de substances médicamenteuses à base d'inhibiteur de transport de polyamine et de dfmo
WO2024155777A2 (fr) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions et techniques de traitement du syndrome des ovaires polykystiques (sopk) et de l'endométriose
WO2024155775A2 (fr) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions et techniques de traitement du syndrome des ovaires polykystiques (sopk) et de l'endométriose
WO2024158951A2 (fr) * 2023-01-25 2024-08-02 Dare Bioscience, Inc. Compositions et méthodes de traitement de la dysménorrhée

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614557A (en) * 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US20050159493A1 (en) * 1997-10-27 2005-07-21 Mcgrath Michael S. Methods for modulating macrophage proliferation using polyamine analogs
US20070078187A1 (en) * 2005-09-23 2007-04-05 Pathologica, Llc. Methods for treating viral infections using polyamine analogs
US20080262092A1 (en) * 2007-03-09 2008-10-23 Pathologica Llc. Regulation of osteopontin

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) * 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5698563A (en) 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
EP1459744A3 (fr) 1996-09-13 2004-12-15 University Of Florida Research Foundation, Inc. Procédé inhibant la biosynthèse de l'eif5a
AR009380A1 (es) 1996-10-21 2000-04-12 Sumitomo Chemical Co Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico
US6083496A (en) 1996-10-22 2000-07-04 Universite Laval Polyamine transport inhibitors
AU758570B2 (en) 1997-07-15 2003-03-27 Mediquest Therapeutics, Inc. Novel polyamine analogues as therapeutic and diagnostic agents
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6169115B1 (en) * 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
WO2002038105A2 (fr) 2000-11-08 2002-05-16 Slil Biomedical Corporation Nouveaux conjugues d'acide amine et d'analogues de polyamine utiles en tant qu'agents anticancer
DE60029944T2 (de) 1999-04-30 2007-04-05 Cellgate, Inc., Redwood City Polyamine und ihre therapeutische verwendung
US6544541B1 (en) 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
JP4253503B2 (ja) 2001-01-08 2009-04-15 メディクエスト セラピューティックス インク 疎水性ポリアミン類似体及びそれらの使用方法
US7045550B2 (en) 2001-08-07 2006-05-16 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US6924095B2 (en) 2001-08-15 2005-08-02 The Regents Of The University Of California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
WO2004069174A2 (fr) 2003-01-31 2004-08-19 Slil Biomedical Corporation Suivi et de traitement de la sclerose laterale amyotrophique
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
WO2005041988A1 (fr) 2003-10-22 2005-05-12 University Of Florida Procédé et composition de soulagement de la douleur
EP1730100A1 (fr) 2004-03-29 2006-12-13 MediQuest Therapeutics, Inc. Analogues de polyamine qui activent le dephasage anti-enzyme
US7445794B1 (en) 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
CA2617150C (fr) 2005-07-29 2016-06-14 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Utilisation d'inhibiteurs de la chk2 kinase pour le traitement du cancer
WO2007040535A1 (fr) 2005-10-03 2007-04-12 Cellgate, Inc. Utilisation d'analogues de polyamine pour le traitement et la prévention de polypes intestinaux
EP2046874A2 (fr) * 2006-07-28 2009-04-15 Exatec, LLC. Panneau de fenêtre automobile ayant un apprêt de polyuréthane
US20110091418A1 (en) 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
WO2008112251A1 (fr) 2007-03-14 2008-09-18 Progen Pharmaceuticals, Inc. Analogues de polyamine contenant des groupes cyclopropyle comme thérapies de la maladie
WO2009018368A1 (fr) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Traitement d'association à base d'amplificateur du nmda (n-méthyl-d-aspartate), d'inhibiteur de transporteur de glycine, d'inhibiteur de d-amino acide oxydase pour des troubles neuropsychiatriques
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2453886B1 (fr) 2009-07-16 2018-12-12 Pathologica LLC Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
EP2283830A1 (fr) 2009-07-23 2011-02-16 Actogenix N.V. Revêtement de capsule entérique aqueuse
NO2665471T3 (fr) 2011-01-19 2018-05-26
CA2896977C (fr) 2013-01-08 2021-12-07 Pathologica Llc Methodes et compositions pour le traitement des troubles de demyelinisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614557A (en) * 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US20050159493A1 (en) * 1997-10-27 2005-07-21 Mcgrath Michael S. Methods for modulating macrophage proliferation using polyamine analogs
US20070078187A1 (en) * 2005-09-23 2007-04-05 Pathologica, Llc. Methods for treating viral infections using polyamine analogs
US20080262092A1 (en) * 2007-03-09 2008-10-23 Pathologica Llc. Regulation of osteopontin

Also Published As

Publication number Publication date
US20170290788A1 (en) 2017-10-12
JP2018127460A (ja) 2018-08-16
CN104997762A (zh) 2015-10-28
DK2453886T3 (en) 2019-03-25
US8258186B2 (en) 2012-09-04
CN102686222B (zh) 2015-06-24
US8609734B2 (en) 2013-12-17
WO2011009039A2 (fr) 2011-01-20
AU2016266049B2 (en) 2018-10-18
US20120289604A1 (en) 2012-11-15
JP6883930B2 (ja) 2021-06-09
HK1176548A1 (en) 2013-08-02
AU2016266049A1 (en) 2016-12-22
US20110112199A1 (en) 2011-05-12
NZ597488A (en) 2014-10-31
EP2453886A4 (fr) 2012-12-05
NZ715686A (en) 2017-08-25
EP2453886A2 (fr) 2012-05-23
EP3473247A1 (fr) 2019-04-24
ES2715173T3 (es) 2019-06-03
AU2010273277A1 (en) 2012-02-02
NZ628513A (en) 2016-01-29
US9616035B2 (en) 2017-04-11
EP2453886B1 (fr) 2018-12-12
JP2020063258A (ja) 2020-04-23
CN102686222A (zh) 2012-09-19
BR112012000862A8 (pt) 2018-01-09
US20140051765A1 (en) 2014-02-20
AU2010273277B2 (en) 2016-12-22
BR112012000862A2 (pt) 2017-10-31
CA2768018A1 (fr) 2011-01-20
CA2768018C (fr) 2019-08-27
JP6112449B2 (ja) 2017-04-12
CN104997762B (zh) 2019-03-08
JP2016065045A (ja) 2016-04-28
JP2012533565A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
WO2011009039A3 (fr) Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
TN2011000414A1 (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof
EP4219465A3 (fr) Inhibiteurs de prmt5 et leurs utilisations
MX342643B (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
MX2012004780A (es) Inhibidores de akt.
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
IN2012DN02805A (fr)
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
WO2012021629A3 (fr) Nouveaux agonistes du récepteur dopaminergique d3 pour traiter la dyskinésie dans la maladie de parkinson
WO2009152356A3 (fr) Composés et compositions utiles pour le traitement de la malaria
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
WO2010003313A8 (fr) Chlorhydrate d’icotinib, synthèse, forme cristallographique, combinaison médicale et utilisations
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
EP2431366A4 (fr) Nouveau composé conjugué de chlore e6-acide folique, procédé de préparation de ce composé et composition pharmaceutique contenant ledit composé pour le traitement du cancer
WO2009085270A3 (fr) Traitement d'états fibreux
WO2012070062A3 (fr) Nouveau polymorphe de chlorhydrate de nilotinib
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
WO2012100043A3 (fr) Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2009142428A3 (fr) Composition pharmaceutique destinée au traitement de l'éjaculation précoce
MX2012011382A (es) Nuevo polimero.
UA103996C2 (en) Ivabradine hydrobromide
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080041853.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10800602

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010273277

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 80/MUMNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010800602

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2768018

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012520810

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2010273277

Country of ref document: AU

Date of ref document: 20100716

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012000862

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112012000862

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012000862

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120113